PHASE I CLINICAL TRIAL TARGETING CD20+NON-HODGKIN'S LYMPHOMA (NHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT WITH ANTI-CD3 x ANTI-CD20 BISPECIFIC ANTIBODY ARMED T CELLS

被引：1
|
作者：
Lum, L. G. [1 ]
Thakur, A. [1 ]
Ratanatharathorn, V [1 ]
Al-Kadhimi, Z. [1 ]
Paul, E. [1 ]
Skuba, C. [2 ]
Steel, P. [1 ]
Ayash, L. [1 ]
Abidi, M. [1 ]
Wedge, J. [1 ]
Uberti, J. P. [1 ]
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Michigan State Univ, Coll Vet Med, E Lansing, MI 48824 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2010.12.027
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
23
引用
收藏
页码：S158 / S159
页数：2
相关论文
共 50 条
  • [31] A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
    Patel, Krish
    Riedell, Peter A.
    Tilly, Herve
    Ahmed, Sairah
    Michot, Jean-Marie
    Ghesquieres, Herve
    de Collela, Jean Marc Schiano
    Chanan-Khan, Asher
    Bouabdallah, Kamal
    Tessoulin, Benoit
    Iyengar, Sunil
    Long, Meixiao
    Clynes, Raphael
    Kanodia, Jitendra
    Bao, Lei
    Ding, Ying
    Jin, Jianhua
    Ainsworth, William B.
    Garcha, Raman
    Kye, Steve
    Phillips, Tycel J.
    BLOOD, 2022, 140 : 9470 - 9472
  • [32] Peripheral T-cell lymphoma after anti-CD20 antibody therapy - In reply
    Maloney, DG
    Davis, T
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1636 - 1637
  • [33] Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design
    Hosseini, Iraj
    Gadkar, Kapil
    Stefanich, Eric
    Li, Chi-Chung
    Sun, Laura
    Chu, Yu-Waye
    Ramanujan, Saroja
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [34] Dissection of GvHD and GvL by FBTA05, a novel trifunctional anti-CD3 x anti-CD20 antibody
    Buhmann, R.
    Stanglmaier, M.
    Simoes, B.
    Menzel, H.
    Peschel, C.
    Ruf, P.
    Lindhofer, H.
    Kolb, H. -J.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S123 - S123
  • [35] Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
    Shah, Nirav Niranjan
    Zhu, Fenlu
    Schneider, Dina
    Taylor, Carolyn
    Krueger, Winfried
    Worden, Andrew
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Novel combination of anti-CD22 radioimmunotherapy and anti-CD20 immunotherapy targeting two different antigens in non-Hodgkin lymphoma (NHL): Initial clinical experience
    Tomblyn, Michael
    Elstrom, Rebecca
    Himelstein, Andrew
    Kio, Ebenezer
    Sharkey, Robert
    Rojo, Jonathan
    Wegener, William
    Goldenberg, David
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [37] Systems Pharmacology Modeling to Support Clinical Development of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody
    Hosseini, Iraj
    Gadkar, Kapil
    Stefanich, Eric
    Li, Chi-Chung
    Sun, Laura
    Chu, Yu-Waye
    Ramanujan, Saroja
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S57 - S57
  • [38] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
    Morschhauser, Franck
    Leonard, John P.
    Fayad, Luis
    Coiffier, Bertrand
    Petillon, Marie-Odile
    Coleman, Morton
    Schuster, Stephen J.
    Dyer, Martin J. S.
    Horne, Heather
    Teoh, Nick
    Wegener, William A.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
  • [39] Radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL) with I-131 anti-CD20 monoclonal antibody (Bexxar™).: Preliminary results
    Antonescu, C
    Buchegger, F
    Kosinski, M
    Ketterer, N
    Kovacsovics, T
    Helg, C
    Delaloye, AB
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 980 - 980
  • [40] Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
    Sharkey, RM
    Karacay, H
    Chang, CH
    McBride, WJ
    Horak, ID
    Goldenberg, DM
    LEUKEMIA, 2005, 19 (06) : 1064 - 1069
12345